文献速递衰弱、肌少症与跌倒老年综合评估

从单一血液生物标志物到肌少症联合生物标志物:韩国衰弱与老龄化队列研究的经验

From a Solitary Blood-Derived Biomarker to Combined Biomarkers of Sarcopenia: Experiences From the Korean Frailty and Aging Cohort Study.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2025-01-01

本文基于韩国衰弱与老龄化队列研究数据,综述了肌少症血液生物标志物的研究经验,涵盖游离睾酮、肌肉生长抑制素、FGF-21、GDF-15、P3NP、肌酐类标志物、EPA、DHA、BDNF及代谢物等。研究发现GDF-15水平与肌少症患病率相关但与发病率无关,P3NP和BDNF可能反映肌肉质量而非数量,红细胞EPA和DHA水平与步速或握力相关,多标志物风险评分诊断准确性高于任一单一标志物。

要点

  • GDF-15与肌少症患病率相关,但与发病率无关。
  • P3NP和BDNF可能反映肌肉质量而非肌肉数量。
  • 多标志物风险评分诊断肌少症准确性高于单一标志物。

核心结论

  • 多生物标志物风险评分诊断肌少症的准确性高于任何单一生物标志物。
  • GDF-15水平与肌少症患病率相关,但与肌少症发病率无关。
  • 血浆P3NP和BDNF水平可能是肌肉质量的生物标志物而非肌肉数量的生物标志物。
  • 红细胞EPA和DHA水平较低与步速慢相关,红细胞EPA水平与握力低相关。

研究设计与样本

  • 基于韩国衰弱与老龄化队列研究(Korean Frailty and Aging Cohort Study)队列数据的综述性分析。

主要发现

  • 游离睾酮、肌肉生长抑制素、FGF-21、GDF-15、P3NP、肌酐类标志物、EPA、DHA、BDNF及代谢物(脯氨酸、丙氨酸、色氨酸)等被纳入分析。
  • 研究尝试解释肌肉生长抑制素和FGF-21水平与肌少症关系中的矛盾性发现。
  • 研究开发了肌少症多生物标志物风险评分,其诊断准确性高于任一单一生物标志物。

关键数值与推荐

  • GDF-15水平与肌少症患病率相关,但与肌少症发病率无关。
  • 血浆P3NP和BDNF水平可能是肌肉质量的生物标志物而非肌肉数量的生物标志物。
  • 红细胞EPA和DHA水平较低与步速慢相关,红细胞EPA水平与握力低相关。
  • 多生物标志物风险评分诊断肌少症的准确性高于任何单一生物标志物。

临床怎么用

  • 临床可关注GDF-15用于肌少症患病风险评估,而非发病预测。
  • P3NP和BDNF可作为评估肌肉质量的参考指标。
  • 红细胞EPA和DHA水平可用于辅助评估步速和握力相关风险。
  • 多生物标志物风险评分可作为肌少症诊断的辅助工具,优于单一标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sarcopenia is recognized as a complex and multifactorial disorder that includes nutritional deficiency, inactivity, proinflammatory status, hormonal changes, neurological degeneration, and metabolic disturbances. It's pathogenesis is not fully understood. Therefore, identifying specific biomarkers of sarcopenia will help us understand its pathophysiology. The most frequently reported blood-derived biomarkers of sarcopenia are growth factors, neuromuscular junctions, endocrine systems, mitochondrial dysfunction, inflammation-mediated and redox processes, muscle protein turnover, blood metabolomics, and behavior-mediated biomarkers. Here, we address the implications of sarcopenia biomarkers based on our research experience with Korean Frailty and Aging Cohort Study cohort data. It includes free testosterone, myostatin, fibroblast growth factor 21 (FGF-21), growth differentiation factor 15 (GDF-15), procollagen type III N-terminal peptide (P3NP), creatinine-based biomarkers, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), brain-derived neurotrophic factor (BDNF), metabolites (proline, alanine, tryptophan), and multi-biomarker risk score. We attempted to explain the paradoxical findings of myostatin and FGF-21 levels in relation to sarcopenia. GDF-15 levels were associated with sarcopenia prevalence but not its incidence. Plasma P3NP and BDNF levels may be biomarkers of muscle quality rather than quantity. Lower erythrocyte eicosapentaenoic acid (EPA) and docosahexaenoic acid levels were associated with slow gait speed, and erythrocyte EPA levels were associated with low handgrip strength. We developed a multi-biomarker risk score for sarcopenia and found that its accuracy in diagnosing sarcopenia was higher than that of any single biomarker.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Won CW, Kim M, Shin HE, et al. From a Solitary Blood-Derived Biomarker to Combined Biomarkers of Sarcopenia: Experiences From the Korean Frailty and Aging Cohort Study. J Gerontol A Biol Sci Med Sci. 2025. PMID: 39417263. doi:10.1093/gerona/glae237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。